Look back at pharma news in the week to September 6
By Barbara Obstoj-Cardwell. Editor
Recovery from the post August lull and US Labor Day holidays kicked off last Tuesday with a not mega M&A deal – Vertex Pharma’s $950 million agreed bid for pre-clinical biotech firm Semma Therapeutics and its diabetes candidate – but nonetheless one that attracted attention. Also of note was Japanese drugmaker Sumitomo Dainippon’s offer on Friday to pay $3 billion to acquire a number of “vant” companies from Roivant Sciences. Among research news, Ardelyx thrilled investors with its Phase III results for tenapanor for people with chronic kidney disease on dialysis, and, on the pricing front, the UK’s cost-effectiveness watchdog, the NICE, on Thursday agreed to recommend Novartis’ eye disease gene therapy Luxturna.
Vertex spends nearly $1B on Semma’s unproven diabetes cell tech
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze